Commentator views former Ørsted CEO as potential Novo Nordisk chairman
For life science companies, it's no longer enough to have experts from own industry in the board room, according to business commentator Jens Christian Hansen. He sees many advantages to Novo Nordisk's interest in including former Ørsted CEO Henrik Poulsen in the company board.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
If a life science company includes people from outside the industry in its board, it can turn into a huge advantage – even if they don't have expert knowledge on the industry, according to business commentator Jens Christian Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings buys Canadian life science company
For subscribers
